AX-2026-043701 · MK-677 (Ibutamoren mesylate) · BCH lot BCH-2601-G7291

Section 1

Results

Measured against the index acceptance specification for the non-peptide adjuncts class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	97.97	% area	≥ 98.5	FAIL
Total impurities	RP-HPLC, sum of reported peaks	2.03	% area	≤ 1.5	FAIL
Largest single impurity	RP-HPLC — spiroindane regioisomer	0.98	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	624.2181	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	624.2187	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+1.0	ppm	± 10	PASS
Total peptide content	by difference from the gravimetric mass balance	79.76	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	78.14	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	649.26	mg	500 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	507.332	mg	500 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	101.5	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	4.13	%	≤ 10.0	PASS
Counter-ion (mesylate)	anion-exchange ion chromatography	15.26	%	≤ 12.0	FAIL
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.85	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.41	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	14.03	min	13.86 ± 0.30 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.12	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	75,683	—	≥ 20,000	PASS
Resolution to nearest impurity	vs free base (des-mesylate, −96 Da)	0.19	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 75,683, and skew follows the reported asymmetry factor of 1.12. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.98 % impurity against a 97.97 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	MK-677 (Ibutamoren mesylate) — main peak	14.03	4,761,646	97.97	—
2	spiroindane regioisomer	14.47	47,631	0.98	0.000
3	sulfonamide hydrolysis product (+18 Da)	13.17	28,190	0.58	+18.011
4	O-desmethyl metabolite analogue (−14 Da)	13.51	13,609	0.28	-14.016
5	residual DMF (process solvent)	5.83	5,346	0.11	-551.000
6	free base (des-mesylate, −96 Da)	14.07	3,888	0.08	-96.011
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 624.2181 Da, computed from C27H36N4O5S · CH4O3S. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 624.2187 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	313.1163	313.1166	0.0003	54.2
1+	625.2254	625.2260	0.0006	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	4.13
Counter-ion (mesylate)	ion chromatography	15.26
Residual solvent + inorganic residue	estimated	0.85
Total peptide content	by difference	79.76
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	97.84	97.97	divergence -0.14 pp vs batch median
Total impurities (% area)	2.16	2.03
Largest single impurity (% area)	1.32	0.98
Water (%)	2.0	4.13
Counter-ion (%)	3.1	15.26
Peptide content (%w/w)	97.6	79.76
Endotoxin (EU/mg)	1.00	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 28 d) → laboratory (hand-carried, 9 d) → assay.
Assay date: 11 Mar 2026
Submitted to the index: 22 Mar 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

ms_confirm22 Mar 2026

Two instruments or it is not confirmed, and this record is one instrument. It is a good one instrument, and the index records it as confirmed rather than corroborated for that reason.

isotope_cluster22 Mar 2026

Nothing here rules out a positional isomer with the same formula. Mass cannot; only chromatography can, and the gradient length on this record is the relevant fact for that.

peak_integrator22 Mar 2026

Resolution to the nearest named impurity is reported on this record with no verdict attached, which is the correct handling. A threshold on that figure would penalise compounds for their own impurity profiles.

hplc_ola22 Mar 2026

A longer gradient buys resolution on close-eluting pairs at a linear cost in run time. Janoshik ran 30 min here; the reference method runs 30, and the difference is visible in this figure.

Section 7

Related records

Same batch — lot BCH-2601-G7291 n=7

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043697	BCH-2601-G7291	PeptideMeter	2026-Q1	98.26	4.31	—	Buyer-sourced	1	FAIL
AX-2026-043698	BCH-2601-G7291	Nordanalyt	2026-Q1	97.67	3.95	97.7	Buyer-sourced	1	FAIL
AX-2026-043699	BCH-2601-G7291	PeptideMeter	2026-Q1	98.09	3.98	97.5	Buyer-sourced	1	FAIL
AX-2026-043700	BCH-2601-G7291	Medutest	2026-Q1	97.98	3.59	89.1	Buyer-sourced	2	FAIL
AX-2026-043702	BCH-2601-G7291	Medutest	2026-Q1	98.41	3.71	92.0	Laboratory-retained	1	FAIL
AX-2026-043703	BCH-2601-G7291	Janoshik	2026-Q1	97.97	4.14	97.4	Buyer-sourced	1	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

All MK-677 (Ibutamoren mesylate) records n=139
All BCH records n=316
All Janoshik records n=3300
All 2026-Q1 records n=895
MK-677 (Ibutamoren mesylate) by supplier
MK-677 (Ibutamoren mesylate) impurity profile

Other recent MK-677 (Ibutamoren mesylate) records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041754	FGP	FGP-2604-K9878	Janoshik	2026-Q2	99.89	5.06	93.8	Buyer-sourced	0	FAIL
AX-2026-042619	SWB	SWB-2605-B6440	Janoshik	2026-Q2	99.30	3.05	—	Buyer-sourced	0	FAIL
AX-2026-041756	FGP	FGP-2604-K9878	Janoshik	2026-Q2	99.62	4.41	89.4	Buyer-sourced	1	FAIL
AX-2026-041751	FGP	FGP-2604-K9878	Janoshik	2026-Q2	99.79	5.69	88.7	Buyer-sourced	1	FAIL
AX-2026-043676	BCH	BCH-2511-G7498	Medutest	2026-Q2	98.86	4.81	99.6	Buyer-sourced	1	FAIL
AX-2026-043678	BCH	BCH-2511-G7498	Kestrel	2026-Q2	98.74	3.73	—	Buyer-sourced	0	FAIL
AX-2026-041753	FGP	FGP-2604-K9878	Janoshik	2026-Q2	99.93	5.72	88.7	Buyer-sourced	1	FAIL
AX-2026-043677	BCH	BCH-2511-G7498	Janoshik	2026-Q2	98.83	4.58	—	Supplier-supplied	0	FAIL

Other recent BCH records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043691	BPC-157	BCH-2603-L7768	Janoshik	2026-Q3	98.66	5.12	—	Supplier-supplied	1	MARGINAL
AX-2026-043693	BPC-157	BCH-2603-L7768	PeptideMeter	2026-Q3	97.82	5.21	94.9	Buyer-sourced	0	FAIL
AX-2026-043686	BPC-157	BCH-2603-L7768	VendorInvestigate	2026-Q3	97.64	5.27	—	Buyer-sourced	0	FAIL
AX-2026-043695	BPC-157	BCH-2603-L7768	Janoshik	2026-Q3	97.61	5.42	—	Buyer-sourced	0	FAIL
AX-2026-043726	N-Acetyl Semax Amide	BCH-2602-E8475	Janoshik	2026-Q3	97.89	9.67	104.2	Buyer-sourced	0	FAIL
AX-2026-043688	BPC-157	BCH-2603-L7768	Janoshik	2026-Q3	97.94	5.56	—	Buyer-sourced	0	FAIL
AX-2026-043658	BPC-157	BCH-2603-G6644	Janoshik	2026-Q3	98.45	4.37	101.8	Supplier-supplied	0	PASS
AX-2026-043692	BPC-157	BCH-2603-L7768	VendorInvestigate	2026-Q3	97.60	5.61	—	Buyer-sourced	0	FAIL